Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Maki Kiso"'
Autor:
Peter J. Halfmann, Kiyoko Iwatsuki-Horimoto, Makoto Kuroda, Yuichiro Hirata, Seiya Yamayoshi, Shun Iida, Ryuta Uraki, Mutsumi Ito, Hiroshi Ueki, Yuri Furusawa, Yuko Sakai-Tagawa, Maki Kiso, Tammy Armbrust, Sam Spyra, Ken Maeda, Zhongde Wang, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-7 (2024)
Abstract During the Omicron wave, previous variants such as BA.2, BA.4, and BA.5 were replaced by newer variants with additional mutations in the spike protein. These variants, BA.4.6, BQ.1.1, and XBB, have spread in different countries with differen
Externí odkaz:
https://doaj.org/article/7b6dc5728b27475ca7af06992e1a8732
Autor:
Ryuta Uraki, Masaki Imai, Mutsumi Ito, Seiya Yamayoshi, Maki Kiso, Nao Jounai, Kazuki Miyaji, Kiyoko Iwatsuki-Horimoto, Fumihiko Takeshita, Yoshihiro Kawaoka
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract Here, we assessed the efficacy of a lipid nanoparticle-based mRNA vaccine candidate encoding the receptor-binding domain (LNP-mRNA-RBD) in mice. Mice immunized with LNP-mRNA-RBD based on the ancestral strain (ancestral-type LNP-mRNA-RBD) sho
Externí odkaz:
https://doaj.org/article/427759ac641440db840a7f2931caa239
Autor:
Maki Kiso, Seiya Yamayoshi, Shun Iida, Yuri Furusawa, Yuichiro Hirata, Ryuta Uraki, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
Abstract Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to most monoclonal
Externí odkaz:
https://doaj.org/article/35fa4f4c459e449fb6a5f48e729cbbac
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
Abstract Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is clinically useful against infection with SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to many mo
Externí odkaz:
https://doaj.org/article/ab06f1a03d3e47acac3756eb1faf1106
Autor:
Ryuta Uraki, Maki Kiso, Kiyoko Iwatsuki-Horimoto, Seiya Yamayoshi, Mutsumi Ito, Shiho Chiba, Yuko Sakai-Tagawa, Masaki Imai, Yukie Kashima, Michiko Koga, Noriko Fuwa, Nobumasa Okumura, Masayuki Hojo, Noriko Iwamoto, Hideaki Kato, Hideaki Nakajima, Norio Ohmagari, Hiroshi Yotsuyanagi, Yutaka Suzuki, Yoshihiro Kawaoka
Publikováno v:
Cell Reports, Vol 42, Iss 12, Pp 113580- (2023)
Summary: EG.5.1 is a subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide. However, the pathogenicity, transmissibility, and immune evasion properties of
Externí odkaz:
https://doaj.org/article/3359de53c5544266aee6bf7bded1cffe
Autor:
Ryuta Uraki, Mutsumi Ito, Maki Kiso, Seiya Yamayoshi, Kiyoko Iwatsuki-Horimoto, Yuko Sakai-Tagawa, Masaki Imai, Michiko Koga, Shinya Yamamoto, Eisuke Adachi, Makoto Saito, Takeya Tsutsumi, Amato Otani, Shuetsu Fukushi, Shinji Watanabe, Tadaki Suzuki, Tetsuhiro Kikuchi, Hiroshi Yotsuyanagi, Ken Maeda, Yoshihiro Kawaoka
Publikováno v:
iScience, Vol 26, Iss 11, Pp 108147- (2023)
Summary: The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAb
Externí odkaz:
https://doaj.org/article/bcc9e8dce069400aa6ad9a843503c254
Autor:
Ryuta Uraki, Shun Iida, Peter J. Halfmann, Seiya Yamayoshi, Yuichiro Hirata, Kiyoko Iwatsuki-Horimoto, Maki Kiso, Mutsumi Ito, Yuri Furusawa, Hiroshi Ueki, Yuko Sakai-Tagawa, Makoto Kuroda, Tadashi Maemura, Taksoo Kim, Sohtaro Mine, Noriko Iwamoto, Rong Li, Yanan Liu, Deanna Larson, Shuetsu Fukushi, Shinji Watanabe, Ken Maeda, Zhongde Wang, Norio Ohmagari, James Theiler, Will Fischer, Bette Korber, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Omicron subvariants may differ in their replicative fitness and their potential to cause more severe disease. In this study, the authors characterized Omicron BA.2.75 in a hamster model and found that it replicates more efficiently in the lungs than
Externí odkaz:
https://doaj.org/article/9b470aadf40f4e12978de00269fa763e
Autor:
Takashin Nakayama, Tatsuhiko Azegami, Maki Kiso, Masaki Imai, Ryuta Uraki, Kaori Hayashi, Akihito Hishikawa, Norifumi Yoshimoto, Ran Nakamichi, Erina Sugita-Nishimura, Eriko Yoshida-Hama, Yoshihiro Kawaoka, Hiroshi Itoh
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global pandemic. Although several vaccines targeting SARS-CoV-2 spike proteins protect against COVID-19 infection, mutations affe
Externí odkaz:
https://doaj.org/article/b635848b23e9431d8855a70f50c9a002
Autor:
Nobuyo Higashi-Kuwata, Kohei Tsuji, Hironori Hayashi, Haydar Bulut, Maki Kiso, Masaki Imai, Hiromi Ogata-Aoki, Takahiro Ishii, Takuya Kobayakawa, Kenta Nakano, Nobutoki Takamune, Naoki Kishimoto, Shin-ichiro Hattori, Debananda Das, Yukari Uemura, Yosuke Shimizu, Manabu Aoki, Kazuya Hasegawa, Satoshi Suzuki, Akie Nishiyama, Junji Saruwatari, Yukiko Shimizu, Yoshikazu Sukenaga, Yuki Takamatsu, Kiyoto Tsuchiya, Kenji Maeda, Kazuhisa Yoshimura, Shun Iida, Seiya Ozono, Tadaki Suzuki, Tadashi Okamura, Shogo Misumi, Yoshihiro Kawaoka, Hirokazu Tamamura, Hiroaki Mitsuya
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Effective antivirals are critical for combatting SARS-CoV-2 infections. Here, the authors develop two orally available small molecules, which specifically inhibit the activity of the SARS-CoV-2 main protease and potently block the infectivity and rep
Externí odkaz:
https://doaj.org/article/0a9319e808d143a0af10cb89193b1a4f
Autor:
Hiroshi Ueki, Maki Kiso, Yuri Furusawa, Shun Iida, Seiya Yamayoshi, Noriko Nakajima, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Publikováno v:
Viruses, Vol 16, Iss 4, p 537 (2024)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) often causes severe viral pneumonia. Although many studies using mouse models have examined the pathogenicity of SARS-CoV-2, COVID-19 pathogenesis remains poorly understood. In vivo imaging
Externí odkaz:
https://doaj.org/article/1d7d7785c8464f9e9ed6aad8e2a15ae1